ACUTE MYELOID LEUKEMIA WITH CUTANEOUS INFILTRATION AND RESPONSE TO TREATMENT WITH AZACITIDINE PROTOCOL ASSOCIATED WITH HIGH DOSES OF VITAMIN

ACUTE MYELOID LEUKEMIA WITH CUTANEOUS INFILTRATION AND RESPONSE TO TREATMENT WITH AZACITIDINE PROTOCOL ASSOCIATED WITH HIGH DOSES OF VITAMIN

Objective: To report a case of acute myeloid leukemia (AML) with cutaneous infiltration and response to the AZAVIT-ABCDEF protocol (Plataforma Brasil CAAE: 53015421.0.0000.5463). Methods: to describe the single clinical case carried out through data collection from medical records and literature rev...

Full description

Bibliographic Details
Main Authors:	SLBG Oliveira, MM Garcia, VM Sthel, VLP Figueiredo
Format:	Article
Language:	English
Published:	Elsevier 2023-10-01
Series:	Hematology, Transfusion and Cell Therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2531137923006776

Similar Items

EXPLORING THE EFFICACY OF AZACITIDINE AND VENETOCLAX COMBINATION IN TREATING ACUTE MYELOID LEUKEMIA IN CASES OF RELAPSE FOLLOWING AZACITIDINE TREATMENT AND HIGH-DOSE VITAMINS THERAPY
by: VM Sthel, et al.
Published: (2023-10-01)

MYELODYSPLASTIC SYNDROME RESPONDING TO THE AZACITIDINE PROTOCOL ASSOCIATED WITH HIGH DOSES OF VITAMINS
by: VM Sthel, et al.
Published: (2023-10-01)

ACUTE MYELOID LEUKEMIA IN COMPLETE RESPONSE FOR 2 YEARS WITH AZACYTIDINE ASSOCIATED WITH HIGH-DOSE VITAMINS
by: VM Sthel, et al.
Published: (2023-10-01)

AZACYTIDINE (A) ASSOCIATED WITH VITAMINS (B1, C, AND D) IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA.
by: R Conserva, et al.
Published: (2023-10-01)

LEUKAPHERESIS AS A TEMPORIZING MEASURE IN LEUKOSTASIS DUE TO ACUTE MYELOID LEUKEMIA
by: ACP Silva, et al.
Published: (2023-10-01)

CASE REPORT: ACUTE MYELOID LEUKEMIA MANIFESTING FEATURES OF VEXAS SYNDROME IN ELDERLY WOMAN
by: CM Freitas, et al.
Published: (2023-10-01)

MYELOID ACUTE LEUKEMIA WITH INCREASED BASOPHILIC CELLS AND HISTAMINE RELEASE EPISODES
by: JOR Cassiano, et al.
Published: (2023-10-01)

A Case of Leukemia Cutis with Acute Myeloid Leukemia on Azacitidine Therapy
by: Asude Kara, et al.
Published: (2017-05-01)

PLATELET DYSFUNCTION IN A PATIENT WITH CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) AND RECURRENT SUBDURAL HEMATOMA.
by: JPB Júnior, et al.
Published: (2023-10-01)

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
by: Ian M. Bouligny, et al.
Published: (2023-05-01)

P557: HEMATOLOGIC IMPROVEMENTS WITH IVOSIDENIB + AZACITIDINE COMPARED WITH PLACEBO + AZACITIDINE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA
by: H. Dohner, et al.
Published: (2022-06-01)

CASE REPORT: ADVANCED SYSTEMIC MASTOCYTOSIS ASSOCIATED WITH HEMATOLOGICAL NEOPLASIA
by: VM Sthel, et al.
Published: (2023-10-01)

Azacitidine as salvage therapy for acute myeloid leukemia in a severely ill patient
by: Harry Ross Powers, et al.
Published: (2014-09-01)

A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines.
by: Paul W Hollenbach, et al.
Published: (2010-01-01)

Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine.
by: Pierre Bories, et al.
Published: (2020-01-01)

Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients
by: Sylvain Garciaz, et al.
Published: (2022-04-01)

Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia
by: Friedrich Stölzel, et al.
Published: (2023-01-01)

Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
by: Leiming Xia, et al.
Published: (2023-05-01)

BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes
by: Fernando Vieira Pericole, et al.
Published: (2019-01-01)

Azacitidine and lenalidomide as an alternative treatment for refractory acute myeloid leukemia: a case report
by: Juliana Todaro, et al.

PB1857: VENETOCLAX, AZACITIDINE, COMBINED WITH LOW-DOSE CYTARABINE IN OLDERLY OR UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
by: Xiao Han, et al.
Published: (2023-08-01)

Azacitidine combined with low dose Venetoclax and Azole in treatment-naive, elderly patient with acute myeloid leukemia: A case report
by: Jean Zeghondy, et al.
Published: (2020-09-01)

P556: CHANGES IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA RECEIVING IVOSIDENIB + AZACITIDINE OR PLACEBO + AZACITIDINE
by: A. Schuh, et al.
Published: (2022-06-01)

P430: MOLECULAR CHARACTERIZATION OF CLINICAL RESPONSE IN NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACEBO + AZACITIDINE
by: S. de Botton, et al.
Published: (2022-06-01)

PB1862: VENETOCLAX AND AZACITIDINE THERAPY IN ACUTE MYELOID LEUKEMIA PATIENTS WITH SEVERE RENAL IMPAIRMENT
by: Ryosuke Naka, et al.
Published: (2023-08-01)

Clinical Utility of Azacitidine in the Management of Acute Myeloid Leukemia: Update on Patient Selection and Reported Outcomes
by: Moreno Vanegas Y, et al.
Published: (2022-12-01)

Azacitidine prolongs overall survival in older patients with Acute Myeloid Leukemia (AML) with poor prognostic karyotypes
by: Doehner, H, et al.
Published: (2017)

Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia.
by: Craddock, C, et al.
Published: (2013)

Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia
by: Craddock, C, et al.
Published: (2013)

Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia
by: DiNardo, CD, et al.
Published: (2020)

PB1817: THE ADDITION OF ZALCITABINE TO ACUTE MYELOID LEUKEMIA TREATMENT MAY IMPROVE AZACITIDINE AND VENETOCLAX COMBINATION
by: Álvarez-Galeano Sofía, et al.
Published: (2023-08-01)

Venetoclax-Azacitidine Bridging PTCy-haplo-PBSCT for Refractory Acute Myeloid Leukemia with IDH2 Mutations
by: Yusuke Daido, et al.
Published: (2023-09-01)

High rate of invasive fungal infections during early cycles of azacitidine for patients with acute myeloid leukemia
by: Sing-Ting Wang, et al.
Published: (2022-11-01)

The Role of Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia: Results of a Retrospective Multicenter Study
by: Anıl Tombak, et al.
Published: (2016-11-01)

Durable remission of acute myeloid leukemia in an elderly patient following a limited course of azacitidine and venetoclax
by: Hamid Ehsan, et al.
Published: (2022-01-01)

Retrospective, real‐life study of venetoclax plus azacitidine or low‐dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy
by: Louise Laloi, et al.
Published: (2023-03-01)

Azacitidine Treatment in Patients with Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia According to their Cytogenetic Findings
by: Nikolova D., et al.
Published: (2021-10-01)

Bridging-to-transplant with azacitidine for myelodysplastic syndrome and acute myeloid leukemia, reduces the incidence of acute graft-versus-host disease
by: Koichi Murakami, et al.
Published: (2017-06-01)

MYELODYSPLASIA/MYELOPROLIFERATIVE WITH RING SIDEROBLAST AND THROMBOCYTOSIS OR UNCLASSIFIABLE (MDS/MPNI)
by: MM Garcia, et al.
Published: (2023-10-01)

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care
by: Döhner, H, et al.
Published: (2018)